Will a divestiture save the UnitedHealth Group-Amedisys deal?

The latest stories trending on MedCity News.

Editor's Pick

Top Story Will A Divestiture Save the UnitedHealth Group-Amedisys Deal? Amedisys and UnitedHealth Group plan to divest care centers to an affiliate of VitalCaring Group. Several experts said this will likely clear the way for the companies' merger. Sponsored Integrated Enrollment Platforms and Consumer Assistance Centers: The Strongest Advantage for State-Based Exchanges In the ever-evolving landscape of state-based health insurance exchanges, the convergence of technology and customer service is reshaping how these exchanges operate. The increasing advent of automation and artificial intelligence (AI) is rapidly dismantling the traditional business model that relies on the siloing of technology and customer service centers. Learn More INVEST Digital Health: Why Attend? Are you a healthcare professional or stakeholder? Here are the top two reasons why INVEST Digital Health is the must-attend event for you: Expert Insights: Learn from renowned thought-leaders, see confirmed speakers here: Speakers - MedCity INVEST (medcityinvestconference.com) Networking Hub: Connect with fellow innovators, investors, and entrepreneurs to exchange ideas, collaborate, and build relationships. Capitalize on the opportunity to learn, grow, and connect with healthcare's brightest minds at INVEST Digital Health on September 18 at Pegasus Park in Dallas!  Register Now and Save $150

Featured News

Check Out the Roster of Healthcare Innovators Taking Part in INVEST Digital Health in Dallas The roster of speakers at INVEST Digital Health scheduled for September 18 in Dallas includes executives from health systems, healthcare entrepreneurs, and more. Register today! Hospital M&A Activity Remained Strong In Q2, Kaufman Hall Says The number of hospital M&A deals may have fallen from Q1 to Q2 of this year, but that doesn't mean that the hospital M&A space is lacking vitality, according to a new Kaufman Hall report. Rather, it means that the hospital M&A is shifting its emphasis from scale to strategy. Ipsen Turns to China-Based Biotech to Get Another ADC Cancer Drug Ipsen has acquired global rights to a Foreseen Biotechnology antibody drug conjugate developed for an undisclosed cancer target. This is Ipsen's second ADC deal in three months, following its acquisition of rights to a ROR1-targeting ADC from Sutro Biophrama. Closing the Gap in Medications for the Treatment of Alcohol Use Disorder (AUD) By understanding that AUD is a diagnosable and treatable medical condition with individualized impact, we can tailor treatments to meet patients' specific needs. Effective treatment for AUD is multifaceted, involving medical, psychological, and social support. The Opportunity for Digital Innovation in Oncology Drug Development Solving three major challenges in the development of new oncology drugs

Resources

Pivot Podcast: The Evolution of Pharmacies with Rick Ratliff Rick Ratliff, a pharmacy industry veteran who was for a time CEO of Surescripts, built a national digital prescription network connecting doctors to pharmacies. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe